Pancreatic Cancer

2 articles

Medical researcher examining a glowing molecular model of Daraxonrasib, with hopeful patients in the background, symbolizing a breakthrough in pancreatic cancer treatment.

Daraxonrasib Doubles Survival in Pancreatic Cancer Treatment Trials

In a recent clinical trial, patients with advanced pancreatic cancer receiving Daraxonrasib lived more than twice as long as those on standard chemotherapy.

David Grossman·June 19, 2026

Microscopic view of cancer cells being targeted by a glowing therapeutic agent, representing Revolution Medicines' experimental drug.

Cosmos & Space

Revolution Medicines' Experimental Pancreatic Cancer Drug Shows Promise

Revolution Medicines' experimental drug daraxonrasib doubled the median overall survival for patients with metastatic pancreatic cancer to 13.2 months in its pivotal Phase 3 trial.

David Grossman·May 31, 2026